Friday, January 31, 2025 8:30:02 AM
Thought for the day :
The UK MHRA Marketing Authorisation Application was submitted on the 20th December 2023.
They have had a very long time to find reasons to reject our application but have not done so to date.
1) DCVax-L was the first ever medicine to be awarded 'Promising Innovative Medicine' (PIM) designation by UK.
2}UK MHRA has allowed DCVax to be given to patients for over four years on a 'Specials' compassionate use program, despite not yet having MAA approval. No issues in terms of either Safety or efficacy have ever been raised.
3) DCVax has a totally 'benign' safety profile.
4) $nwbo was given approval (fast-tracked) of the Pediatric Investigation plan (PIP) BY MHRA which forms a pre-requisite for Application for approval of a New Medicine for Adult patients. Importantly, The external controls will be identified using the same methodology as was used to pre-specify the external controls in the Statistical Analysis Plan for the Company’s Phase III trial in adult patients.
5) DCVax successfully completed the first phase 3 trial of a systemic treatment in 17 years to show a significant extension of mOS in nGBM
6) DCVax successfully completed the first phase 3 trial of any type of treatment in 27 years to show a significant extension of mOS in rGBM
7) DCVax successfully completed one of the first, if not the first, phase 3 trials to show meaningful increases in the long-term tails of the survival curves in both nGBM and rGBM
8) DCVax is the 'Gift that just keeps on giving' 🤣
Plenty to be positive about as we await the imminent MHRA decision.
#dcvax $nwbo #gbm
— Peter Davis (@peter_brit) January 31, 2025
Thought for the day :
The UK MHRA Marketing Authorisation Application was submitted on the 20th December 2023.
They have had a very long time to find reasons to reject our application but have not done so to date.
1) DCVax-L was the first ever medicine to be… pic.twitter.com/0sC6Q00ISM
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2025 09:23:24 PM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
C2 Blockchain Reports 803 Million DOG (Bitcoin) Holdings Following Strategic Accumulation of Bitcoin-Native Digital Assets • CBLO • Mar 10, 2026 8:00 AM
RENI Completes Due Diligence on Target Acquisition; Confirms Strong Asset Base and Operational Performance • RENI • Mar 5, 2026 10:15 AM
BlackStar Engages in Talks with U.S. Senate Banking Committee Team Covering the Digital Asset Market Clarity Act • BEGI • Mar 4, 2026 4:47 PM
